Abstract:Background Nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic without effective treatment currently available. NAFLD is characterized by an increase in hepatic de novo lipogenesis (DNL) and inadequate compensatory enhancement in fatty acid oxidation (FAO), which disturbs lipid homeostasis. In NAFLD, lipid metabolism relies heavily on metabolic reprogramming. Moreover, lipid metabolism plays an essential role in switching between lipogenesis and FAO, which is beneficial for the anti-NAFLD therapy. Our recent study demonstrated that the phytochemical tetrahydropalmatine (THP) has positive efficacy in hepatocellular carcinoma (HCC). However, it remains unclear whether the therapeutic benefits of THP are primarily due to delaying the progression of hepatic steatosis to HCC. Purpose This work aimed to systemically evaluate the pharmacological functions and underlying mechanisms of THP in NAFLD using both in vitro and in vivo models. Methods NAFLD models were established using high-fat diet (HFD)-fed mice in vivo and palmitic acid- and oleic acid-challenged hepatocytes in vitro . Metabonomics analysis concomitant with biochemical indices and computational biology assays were performed comprehensively to reveal the key link between the treatment of NAFLD and the AMPK-SREBP-1c-Sirt1 signaling axis. Results Hepatic metabolomics analysis revealed that THP altered lipid metabolism by enhancing FAO and inhibiting glycolysis, tricarboxylic acid cycle, and urea cycle in HFD-fed mice. Analysis of gene expression showed that THP profoundly suppressed hepatic DNL and promoted FAO. THP supplementation not only significantly decreased body/liver weight gain and serum indices but also ameliorated hepatic steatosis. Simultaneously, impaired lipotoxicity was observed in vivo and in vitro after THP supplementation, protecting against steatosis-driven injury. Metabolic phenotype assays showed that THP promoted switching from glycolysis inhibition to FAO enhancement in steatotic cells, resulting in reprogramming lipid metabolism. Mechanistically, THP accelerated lipid oxidation by activating AMPK-SREBP-1c-Sirt1 axis signaling. Applying molecular docking combined with surface plasmon resonance and cellular thermal shift assay target engagement, as well as siRNA assays, AMPKα was confirmed as a direct molecular target of THP. Conclusion In summary, THP ameliorates hepatic steatosis in NAFLD by switching lipid metabolism via the AMPK-SREBP-1c-Sirt1 pathway. This work provides an attractive phytochemical component for therapy against hepatic steatosis in NAFLD.

Phloretin attenuation of hepatic steatosis <i>via</i> an improvement of mitochondrial dysfunction by activating AMPK-dependent signaling pathways in C57BL/6J mice and HepG2 cells

Phloretin attenuation of hepatic steatosis via an improvement of mitochondrial dysfunction by activating AMPK-dependent signaling pathways in C57BL/6J mice and HepG2 cells

Activation of AMPK/Sirt3 Pathway by Phloretin Reduces Mitochondrial ROS in Vascular Endothelium by Increasing the Activity of MnSOD Via Deacetylation

Activation of Nrf2 by phloretin attenuates palmitic acid-induced endothelial cell oxidative stress via AMPK-dependent signaling.

Phloretin promotes adipocyte differentiation in vitro and improves glucose homeostasis in vivo.

Phloretin Ameliorates Diabetes-Induced Endothelial Injury Through AMPK-dependent Anti-Endmt Pathway

Hepatotoxicity and Endothelial Dysfunction Induced by High Choline Diet and the Protective Effects of Phloretin in Mice

Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis

An Effect of Dietary Phloretin Supplementation on Feed Intake in Mice

Phloridzin Ameliorates Lipid Deposition in High-Fat-Diet-Fed Mice with Nonalcoholic Fatty Liver Disease <i>via</i> Inhibiting the mTORC1/SREBP-1c Pathway

Phloretin Prolongs Lifespan of Caenorhabditis Elegans Via Inhibition of NDUFS1 and NDUFS6 at Mitochondrial Complex Ⅰ

Phloretin Prolongs Lifespan of Caenorhabditis elegans via Inhibition of NDUFS1 and NDUFS6 at Mitochondrial Complex I

Phloretin Alleviates Palmitic Acid-Induced Oxidative Stress in HUVEC Cells by Suppressing the Expression of LncBAG6-AS.

Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway

Phloretin inhibits glucose transport and reduces inflammation in human retinal pigment epithelial cells

Phytol Increases Adipocyte Number and Glucose Tolerance Through Activation of PI3K/Akt Signaling Pathway in Mice Fed High-Fat and High-Fructose Diet.

Averrhoa Carambola Free Phenolic Extract Ameliorates Nonalcoholic Hepatic Steatosis by Modulating Mircorna-34A, Mircorna-33 and AMPK Pathways in Leptin Receptor-Deficient Db/db Mice.

Phloretin alleviates palmitic acid-induced oxidative stress in HUVEC cells by suppressing the exprssion of LncBAG6-AS

Hepatoprotective Effects of Phloretin Against Ccl4-Induced Liver Injury in Mice

C2C12 Mouse Myoblasts Damage Induced by Oxidative Stress Is Alleviated by the Antioxidant Capacity of the Active Substance Phloretin

Amelioration of Alcoholic Liver Steatosis by Dihydroquercetin Through the Modulation of AMPK-Dependent Lipogenesis Mediated by P2X7R-NLRP3-Inflammasome Activation